PAP
VOR icon

Persistent Asset Partners’s Vor Biopharma VOR Stock Holding History

Persistent Asset Partners’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-10,798
Closed -$141K – 482
2025
Q4 		$141K Buy
+10,798
New +$201K 0.06% 249

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Persistent Asset Partners's VOR Position: Q1 2026 in Review

Persistent Asset Partners sold out of Vor Biopharma (VOR) in Q1 2026, closing a stake of 10,798 shares — an estimated $141K sold.

Persistent Asset Partners first reported a position in VOR in Q4 2025 and held it in 1 quarter. The position peaked at $141K in Q4 2025. 80 funds tracked by Wall St. Rank hold VOR as of Q1 2026.

  • Persistent Asset Partners reported no remaining Vor Biopharma position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 10,798 Vor Biopharma shares in Q1 2026, an estimated $141K.
  • Persistent Asset Partners first reported a position in Vor Biopharma in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's Vor Biopharma position peaked at $141K in Q4 2025.
  • 80 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.